MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, CCCC made $6,152K in revenue. -$25,501K in net income. Net profit margin of -414.52%.

Income Overview

Revenue
$6,152K
Net Income
-$25,501K
Net Profit Margin
-414.52%
EPS
-$0.2
Unit: Thousand (K) dollars
Revenue Breakdown
    • Roche Agreement
    • Biogen Agreement
    • MKDGAgreement
    • Betta Agreement

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Revenue from collaboration agreements
6,152 11,016 11,230 6,463
Impairment of long-lived assets
--10,733 -
Restructuring
--0 0
Research and development
24,606 24,982 25,989 26,197
General and administrative
9,331 9,179 8,920 8,767
Impairment loss on right-of-use asset
-0* --
Restructuring
-0* --
Total operating expenses
33,937 34,161 45,642 34,964
Loss from operations
-27,785 -23,145 -34,412 -28,501
Interest and other income, net
2,656 2,780 2,246 2,481
Total other income, net
2,656 2,780 2,246 2,481
Loss before income taxes
--20,365 -32,166 -26,020
Income tax expense
-121 --
Net loss
-25,129 -20,486 -32,166 -26,020
Unrealized (gain) loss on marketable securities
--37 --73
Unrealized loss on marketable securities
-372 -117 -
Comprehensive loss
-25,501 -20,523 -32,049 -26,093
Basic EPS
-0.2 -0.175 -0.44 -0.37
Diluted EPS
-0.2 -0.175 -0.44 -0.37
Basic Average Shares
126,074,555 117,175,738 72,563,311 71,005,743
Diluted Average Shares
126,074,555 117,175,738 72,563,311 71,005,743
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Comprehensive loss-$25,501K (3.16%↑ Y/Y)Interest and otherincome, net$2,656K (-6.54%↓ Y/Y)Net loss-$25,129K (4.53%↑ Y/Y)Unrealized loss onmarketable securities-$372K Total other income,net$2,656K (-6.54%↓ Y/Y)Roche Agreement$2,385K (-4.45%↓ Y/Y)Biogen Agreement$2,000K MKDGAgreement$1,762K (-44.12%↓ Y/Y)Betta Agreement$5K (-98.91%↓ Y/Y)Loss from operations-$27,785K (4.73%↑ Y/Y)Revenue fromcollaboration agreements$6,152K (-15.00%↓ Y/Y)Total operatingexpenses$33,937K (-6.77%↓ Y/Y)Research and development$24,606K (-9.11%↓ Y/Y)General andadministrative$9,331K (0.01%↑ Y/Y)

C4 Therapeutics, Inc. (CCCC)

C4 Therapeutics, Inc. (CCCC)